John Loper
Friday, May 19, 2017
Patiromer for Hyperkalemia Recommended for Marketing in EU
The potassium-binding agent had been seen to safely control mild to moderate hyperkalemia in a phase 2 trial of patients with diabetic nephropathy.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment